Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer.
Jänne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M, Kim DW, Koczywas M, Gold KA, Steuer CE, Murakami H, Yang JC, Kim SW, Vigliotti M, Shi R, Qi Z, Qiu Y, Zhao L, Sternberg D, Yu C, Yu HA. Jänne PA, et al. Among authors: nishio m. Cancer Discov. 2022 Jan;12(1):74-89. doi: 10.1158/2159-8290.CD-21-0715. Epub 2021 Sep 21. Cancer Discov. 2022. PMID: 34548309 Free PMC article. Clinical Trial.
Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Ohyanagi F, Taguchi F, Horai T, Kasahara K, Takeda Y, Shibata K, Shirosaki H, Nishio M. Ohyanagi F, et al. Among authors: nishio m. Jpn J Clin Oncol. 2006 Sep;36(9):547-51. doi: 10.1093/jjco/hyl062. Epub 2006 Jul 26. Jpn J Clin Oncol. 2006. PMID: 16870693 Clinical Trial.
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA Jr, Carbone DP. Taguchi F, et al. Among authors: nishio m. J Natl Cancer Inst. 2007 Jun 6;99(11):838-46. doi: 10.1093/jnci/djk195. J Natl Cancer Inst. 2007. PMID: 17551144
Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.
Hida T, Tamiya M, Nishio M, Yamamoto N, Hirashima T, Horai T, Tanii H, Shi MM, Kobayashi K, Horio Y. Hida T, et al. Among authors: nishio m. Cancer Sci. 2011 Apr;102(4):845-51. doi: 10.1111/j.1349-7006.2010.01839.x. Epub 2011 Feb 8. Cancer Sci. 2011. PMID: 21205086 Free article. Clinical Trial.
Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.
Nishio M, Yamanaka T, Matsumoto K, Kimura H, Sakai K, Sakai A, Sone T, Horiike A, Koizumi F, Kasahara K, Ohira T, Ikeda N, Saijo N, Arao T, Nishio K. Nishio M, et al. Among authors: nishio k. J Thorac Oncol. 2011 Nov;6(11):1889-94. doi: 10.1097/JTO.0b013e3182286d41. J Thorac Oncol. 2011. PMID: 21964526 Free article.
1,470 results